Life Sciences

Southborough-based Veristat is overseeing a new immunotherapy clinical trial for patients with ovarian cancer.

Sunovion Pharmaceuticals' drug Latuda has been approved by Canada's public health agency for the treatment of adolescents with schizophrenia, Sunovion said last week.

Sunovion Pharmaceuticals is divesting its allergy and asthma products to focus more heavily on its products that treat chronic obstructive pulmonary disease.

Biostage, Inc. of Holliston has enough funding to get it through the end of 2018, following a stock purchase worth $3.1 million by one of its investors.

Holliston life sciences company Harvard Bioscience has elected James Green, the former president and CEO of Analogic Corp., as its new board chairman.

Life sciences jobs in Massachusetts hit an all-time high in 2016 and the industry will have thousands of new jobs to fill in the coming years, according to a report released Wednesday morning at a conference in Boston.

A drug that treats major depressive episodes associated with bipolar depression improved symptoms in a statistically significant way in a human clinical study, according to its developer, Sunovion Pharmaceuticals of Marlborough.

Harvard Bioscience, a Hollison life science instrument company, lost more than $1 million in the first quarter as revenue fell from the prior year.

Since its acquisition by a Japanese company just over a year ago, Astellas Institute for Regenerative Medicine has heightened expectations.

The Massachusetts Life Sciences Center (MLSC) on Tuesday announced a new program that will provide grant funding to early-stage life sciences companies.